Skip to main content
TScan Therapeutics, Inc. logo

TScan Therapeutics, Inc. — Investor Relations & Filings

Ticker · TCRX ISIN · US89854M1018 US Professional, scientific and technical activities
Open in API
Filings indexed 310 across all filing types
Latest filing 2024-12-26 Capital/Financing Update
Country US United States of America
Listing US TCRX

About TScan Therapeutics, Inc.

https://www.tscan.com

TScan Therapeutics, Inc. is a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of cancer. The company's approach is centered on discovering highly effective, naturally occurring TCRs and using them to genetically reprogram T cells. This strategy aims to harness the power of the human immune system to deliver safe and effective immunotherapies to patients.

Recent filings

Filing Released Lang Actions
424B5
Capital/Financing Update Classification · 100% confidence The document is a detailed prospectus supplement and accompanying prospectus related to a registered direct offering of pre-funded warrants and common stock. It includes detailed information about the offering terms, risk factors, use of proceeds, dividend policy, and descriptions of capital stock and warrants. The document is filed pursuant to Rule 424(b)(5), which is a SEC rule for prospectus supplements related to securities offerings. The content focuses on capital raising activities and securities issuance rather than financial results, management changes, or regulatory certifications. Therefore, this document is best classified as a Capital/Financing Update (CAP).
2024-12-26 English
8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events that shareholders should know about. The content details the entry into a new loan agreement, termination of a previous loan agreement, and related financial obligations. It includes specific terms of the loan, interest rates, covenants, and collateral. There is no comprehensive financial statement or full financial performance report, so it is not an Annual Report (10-K) or Interim Report (IR). It is not a call transcript, earnings release, or management report. The document primarily provides an update on financing activities, specifically a new loan agreement and repayment of an old loan. Therefore, it fits best under Capital/Financing Update (CAP). The document length is sufficient and contains substantive details about the financing arrangement, not just an announcement or summary, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA).
2024-12-23 English
Director's Dealing 2024
Director's Dealing
2024-12-16 English
8-K
Regulatory Filings Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report used to announce major events or updates by a company. The content includes a press release about updated clinical trial data and a presentation for a key opinion leader event. It discusses trial results, regulatory feedback, and future plans but does not contain comprehensive financial statements or detailed financial analysis. The document is not an earnings release, annual report, or interim report. It is primarily an update on clinical and regulatory developments and includes a presentation. The document is longer than 5,000 characters and contains substantive information, but it is not a full financial report. The nature of the content aligns best with a Regulatory Filing (RNS) as it is a general regulatory announcement and update that does not fit into more specific categories like earnings release or management report. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-12-10 English
FORM 8-K
Capital/Financing Update Classification · 95% confidence The document is a Form 8-K filed with the SEC, which is a current report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934. The content describes a conversion of a loan into common stock shares, detailing the issuance of shares and referencing a Loan and Security Agreement. This is an update on financing activities, specifically a conversion of debt to equity, which fits the category of Capital/Financing Update. The document length is 4302 characters, which is relatively short but contains substantive information about a financing event, not just an announcement of a report. Therefore, it is not a Report Publication Announcement or Regulatory Filing. The document is not an earnings release, annual report, or other financial statement. Hence, the appropriate classification is Capital/Financing Update (CAP).
2024-11-21 English
Director's Dealing 2024
Director's Dealing
2024-11-19 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.